OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds
OncoMethylome Sciences entered into a pharmacogenomic service collaboration with Abbott. Under the terms of the collaboration, OncoMethylome will assist Abbott in profiling tumors. Specifically, OncoMethylome will be testing its DNA methylation biomarkers on Abbott's biological samples.
"We are very pleased to add this collaboration to existing similar agreements and to use our high-throughput methylation platform to efficiently test our methylation biomarkers on biological samples provided by Abbott", commented Dr. Jim DiGuiseppi, Chief Technology Officer of OncoMethylome. "We are pleased that Abbott has chosen OncoMethylome and our methylation technology for this collaboration"
Financial details of the agreement were not disclosed
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Gerresheimer: Substantially increases earnings in second quarter - Adjusted earnings per share surpass prior-year quarter by 34.5%
Bavarian Nordic enters clinical trials with HIV multiantigen vaccine
OctoPlus wins new drug delivery evaluation contract
Mouse stem cell study offers new insights into body fat distribution
Pharmexa adds two strong new members to board of directors
Alnylam Grants Dharmacon License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein
